NFXF Blog
Featured
Congratulations to 2025’s three NFXF Summer Scholars. Meet Susana Lopez-Ignacio, Tanvi Kamra, and Shelby Dauterman!
‘Fishing for a Cureʼ Reels in Over $20,000 This Year!
12 mins read
FORE! Fragile X Annual Golf Event Raises over $63,000 (So Far!)
05 mins read
Mirum Launches Phase 2 Trial of MRM-3379 for Fragile X Syndrome
03 mins read
Relationship Between Intellectual Disability and Behavioral Comorbidity in Children with Fragile X Syndrome
03 mins read
All Articles
[This is an archived page referring to the Seaside Arbaclofen (STX209) clinical trial, which was terminated in 2013.] We have experienced a setback with the cancellation of the extension phase of the STX209 drug trials for Fragile X syndrome, and what have been deemed the technical failures of two other ongoing trials of this drug.
[This is an archived page referring to the Seaside Arbaclofen (STX209) clinical trial, which was terminated in 2013.] By now, many of you have heard that Seaside Therapeutics has decided to end the extension of the trial medication Arbaclofen (STX209).